Axsome Therapeutics Stock Analysis

Axsome Stock Analysis Notes

About 16.0% of the company shares are held by company insiders. The company recorded a loss per share of 4.67. Axsome Therapeutics had not issued any dividends in recent years. Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system disorders in the United States. The company was incorporated in 2012 and is based in New York, New York. Axsome Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 198 people. For more info on Axsome Therapeutics please contact Herriot MD at 212 332 3241 or go to https://www.axsome.com.

Axsome Therapeutics Investment Alerts

Axsome Largest EPS Surprises

View All Earnings Estimates

Axsome Therapeutics Environmental, Social, and Governance (ESG) Scores

Axsome Stock Institutional Investors

Note, although Axsome Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Axsome Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 9.38 B.

Axsome Profitablity

The company has Profit Margin (PM) of (0.41) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.19) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.19.

Management Efficiency

Axsome Therapeutics has return on total asset (ROA) of (0.1979) % which means that it has lost $0.1979 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.755) %, meaning that it created substantial loss on money invested by shareholders. Axsome Therapeutics' management efficiency ratios could be used to measure how well Axsome Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 13th of February 2026, Return On Tangible Assets is likely to drop to -0.53. In addition to that, Return On Capital Employed is likely to drop to -0.78. At this time, Axsome Therapeutics' Other Assets are very stable compared to the past year. As of the 13th of February 2026, Intangibles To Total Assets is likely to grow to 0.15, while Return On Tangible Assets are likely to drop (0.53).

Technical Drivers

As of the 13th of February 2026, Axsome Therapeutics shows the Downside Deviation of 1.71, mean deviation of 1.83, and Risk Adjusted Performance of 0.1227. Axsome Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Axsome Therapeutics standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and expected short fall to decide if Axsome Therapeutics is priced correctly, providing market reflects its regular price of 182.35 per share. Given that Axsome Therapeutics has jensen alpha of 0.4783, we suggest you to validate Axsome Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Axsome Therapeutics Price Movement Analysis

Axsome Therapeutics Insider Trading Activities

Axsome Therapeutics Outstanding Bonds

Axsome Therapeutics Predictive Daily Indicators

Axsome Therapeutics Corporate Filings

Axsome Therapeutics Forecast Models

Axsome Therapeutics' time-series forecasting models are one of many Axsome Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Axsome Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Axsome Therapeutics Bond Ratings

Axsome Therapeutics financial ratings play a critical role in determining how much Axsome Therapeutics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Axsome Therapeutics' borrowing costs.

Axsome Therapeutics Debt to Cash Allocation

Axsome Therapeutics currently holds 192.96 M in liabilities with Debt to Equity (D/E) ratio of 6.2, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Axsome Therapeutics has a current ratio of 2.39, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Axsome Therapeutics' use of debt, we should always consider it together with its cash and equity.

Axsome Therapeutics Total Assets Over Time

Axsome Therapeutics Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Axsome Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Axsome Therapeutics Debt Ratio

63.0

It appears that about 37% of Axsome Therapeutics' assets are financed be debt. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Axsome Therapeutics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Axsome Therapeutics, which in turn will lower the firm's financial flexibility.

Axsome Therapeutics Corporate Bonds Issued

Axsome Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how Axsome Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Axsome shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Axsome Therapeutics. By using and applying Axsome Stock analysis, traders can create a robust methodology for identifying Axsome entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Axsome analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Axsome analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Axsome Therapeutics stock analysis indicators help investors evaluate how Axsome Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Axsome Therapeutics shares will generate the highest return on investment. By understating and applying Axsome Therapeutics stock analysis, traders can identify Axsome Therapeutics position entry and exit signals to maximize returns.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Axsome Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.

Investors evaluate Axsome Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Axsome Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Axsome Therapeutics' market price to deviate significantly from intrinsic value.

Understanding that Axsome Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Axsome Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Axsome Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.